At the recent annual meeting of the American Society of Hematology held in San Diego, researchers reported improved results with certain types of leukemia. These outcomes were achieved by using higher drug dosages to treat early chronic myelogenous leukemia (CML), and equivalent results occurred with a more convenient subcutaneous, rather than intravenous, route for delivering a biologic for chronic lymphocytic leukemia (CLL).